Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27532713 | 0.89 | LMNA (0.52) | LMNARIPK1CYP17A1NPC1RAB9A | |
| SCHEMBL317208 | 0.88 | LMNA (0.61) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL28218362 | 0.88 | LMNA (0.61) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL477567 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL477511 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL7120698 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL8193119 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL22491606 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL477546 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 | |
| SCHEMBL30975296 | 0.86 | LMNA (0.59) | LMNAKDM4EALDH1A1RIPK1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104311503-A | Method for preparing anti-HIV (human immunodeficiency virus) medicine ritonavir | NORTHEAST PHARMACEUTICAL GROUP CO LTD | 2015-01-28 | — | — | CN | claimed |
| CN-102786494-B | The study on the synthesis of ritonavir isomer impurities and control method | HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY CO., LTD. (CN) | 2016-01-06 | — | — | CN | disclosed |
| CN-104311503-A | Method for preparing anti-HIV (human immunodeficiency virus) medicine ritonavir | NORTHEAST PHARMACEUTICAL GROUP CO LTD | 2015-01-28 | — | — | CN | disclosed |
| CN-102898398-B | Method for preparing type I ritonavir polymouphous crystals | SHANGHAI DESANO PHARMACEUTICAL CO LTD | 2015-01-14 | — | — | CN | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1638544-B1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | OXER1, ESRRA, NR5A1 | LMNA 2618/4885KDM4E 773/4885ALDH1A1 1832/4885 |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | AK1, IRAK1, CNKSR1 | LMNA 4621/4885KDM4E 76/4885ALDH1A1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.